Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing the recent approval of BIMZELX (bimekizumab-bkzx) as a treatment for psoriatic arthritis, nonradiographic axial spondyloarthritis and ankylosing spondylitis.

Ticker(s): UCBJY

Who's the expert?

Institution: Rheumatology Therapeutics Medical Center

Board-certified in both rheumatology and internal medicine.
Areas of interest include Rheumatoid Arthritis, Osteoarthritis, Spondyloarthropathies, Lupus, Scleroderma, Mixed Connective Tissue Disease, Sarcoidosis, Osteoporosis, Gout, Inflammatory Myopathies, Vasculitis
Currently manages 500 patients with rheumatoid Arthritis
Familiar with the mechanism of action for Peresolimab

Interview Goal

to discuss the current treatment landscape and the potential of BIMZELX (bimekizumab-bkzx) an IL-17 inhibitor recently approved by the FDA for the treatment of psoriatic arthritis, nonradiographic axial spondyloarthritis and ankylosing spondylitis.

Do you want answers to these questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.